Anti-Mouse CD80/B7-1 Antibody (RM80)
Based on 1 Customer Validation
Anti-Mouse CD80/B7-1 Antibody (RM80) is an anti-mouse CD80/B7-1 IgG2a monoclonal antibody. Anti-Mouse CD80/B7-1 Antibody (RM80) can inhibit the number of tissue-resident memory (TRM) cells. Anti-Mouse CD80/B7-1 Antibody (RM80) can prolong the survival time of transplants combined with CD86 mAb. Anti-Mouse CD80/B7-1 Antibody (RM80) can be used for researches on inflammation conditions and immunology such as viral myocarditis and corneal transplant.
For research use only. We do not sell to patients.
- Purity: 95%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Rat IgG2a kappa
Mouse
CD80/B7-1
Anti-Mouse CD80/B7-1 Antibody (RM80) (300 μg, i.p., twice weekly, for 2 weeks) significantly inhibits the proliferation of E7 specific CD8+ T cells and the formation of tissue-resident memory (TRM) cells in C57BL/6 mice injected with Ad-R9F vaccine[2].
Anti-Mouse CD80/B7-1 Antibody (RM80) (0.1 and 0.25 mg, i.p., on day 0, 2, 4, 6, and 8 after transplantation) significantly prolongs corneal graft survival combined with CD86 mAb in male BALB/c (H-2d) mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:1×109 pfu CVB3 virus injected male C3H/He mice (5 weeks)[1]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection (i.p.), on day 0 and day 3
-
Result:Significantly reduced the area of myocarditis to 6.00 %.
-
Animal Model:1×109 IU Ad-R9F vaccine injected C57BL/6 mice (6-8 weeks)[2]
-
Dosage:300 μg, combined with CD86 mAb (300 μg)
-
Administration:Intraperitoneal injection (i.p.), twice weekly, for 2 weeks
-
Result:Significantly reduced the number of E7 specific CD8+ T cells in the early stages.
Had a relatively small impact in the later stage.
-
Animal Model:Male BALB/c (H-2d) mice (6-8 weeks)[3]
-
Dosage:0.1 and 0.25 mg
-
Administration:Intraperitoneal injection (i.p.), on day 0, 2, 4, 6, and 8 after transplantation
-
Result:Significantly prolonged the survival time of transplants.
Significantly reduced edema and infiltration.
Significantly reduced CD80+ cells.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo CD80 blockade; in vitro CD80 blockade; Flow cytometry
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CD80/B7-1 Antibody (RM80)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Seko Y, et al. Expression of costimulatory molecule CD40 in murine heart with acute myocarditis and reduction of inflammation by treatment with anti-CD40L/B7-1 monoclonal antibodies. Circ Res. 1998 Aug 24;83(4):463-9. [Content Brief]
[2]. van der Gracht ET, et al. Adenoviral vaccines promote protective tissue-resident memory T cell populations against cancer. J Immunother Cancer. 2020 Dec;8(2):e001133. [Content Brief]
[3]. Kagaya F, et al. Inhibition of murine corneal allograft rejection by treatment with antibodies to CD80 and CD86. Exp Eye Res. 2002 Jan;74(1):131-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)